The engineered TCRs, KDA11-01 and KDA11-02, transduced into T cells, demonstrated significant in vitro efficacy in targeting and eliminating malignant tumor cell lines harboring the KRAS G12D mutation within the context of HLA-A*11:01. Here, KRAS is linked to cancer.